Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at developing the company’s immunotherapy assets to address unmet needs in cancer treatment. The facility will serve as a base for advancing Biosyngen’s pipeline of innovative therapies.
Facility Details and Strategic Importance
The 1,300-square-meter facility, located in Solaris @ Tai Seng, Singapore, will be one of the largest of its kind in the country upon completion. Developed by Soilbuild, the building is specifically designed for the Biopharma and Life Science sectors, making it an ideal site for biotechnology companies. The facility is expected to be operational in June 2023 and will produce GMP material for clinical trials in Singapore and the region. In consultation with ACTRIS, the facility will incorporate industry best practices and serve as Biosyngen’s platform for process development in Cell Therapy manufacturing and application filing for its products.
Company Overview and Collaborations
Biosyngen holds exclusive licenses and patented therapies targeting multiple solid tumors and hematological malignancies, including nasopharyngeal cancer, gastric cancer, lymphoma, and posttransplant lymphoproliferative disorders. Operating out of Singapore and Guangzhou, China, Biosyngen has partnered with leading institutions such as A*STAR, Helmholtz Zentrum München, Hannover Medical School, and Sun Yat-Sen University Cancer Center. The company has multiple product pipelines in clinical trials in Singapore, Australia, China, and other locations.
Future Outlook
The establishment of the GMP facility underscores Biosyngen’s commitment to advancing cell therapy solutions for cancer treatment. This strategic move will enhance the company’s capabilities in process development and clinical trial support, ultimately contributing to the global fight against cancer.-Fineline Info & Tech
